Presentatie TiGenix

of 30
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information Report
Category:

Documents

Published:

Views: 57 | Pages: 30

Extension: PDF | Download: 0

Share
Description
At the Forefront of Regenerative Medicine Frank Hazevoets CFO and Company secretary Luc Van de Steen Member of the Board Brussels January 14, 2010 Notice This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, n
Tags
Transcript
    At the Forefront of Regenerative Medicine    Frank Hazevoets CFO and Company secretary Luc Van de Steen Member of the BoardBrusselsJanuary 14, 2010  2 This document does not constitute or form part of any offer or invitation to sell or issue,or any solicitation of any offer to purchase or subscribe for, any shares in the Company,nor shall any part of it nor the fact of its distribution form part of or be relied on inconnection with any contract or investment decision relating thereto, nor does itconstitute a recommendation regarding the securities of the Company.This document may contain forward-looking statements and estimates made by theCompany, including with respect to the anticipated future performance of TiGenix andthe market in which it operates. They include all matters that are not historical facts.Such statements, forecasts and estimates are based on various assumptions andassessments of known and unknown risks, uncertainties and other factors, which weredeemed reasonable when made but may or may not prove to be correct. Actual eventsare difficult to predict and may depend upon factors that are beyond the Company'scontrol. Therefore, actual results, the financial condition, performance or achievementsof TiGenix, or industry results, may turn out to be materially different from any futureresults, performance or achievements expressed or implied by such statements,forecasts and estimates. Forward-looking statements, forecasts and estimates onlyspeak as of the date of this document and no representations are made as to theaccuracy or fairness of such forward-looking statements, forecasts and estimates.TiGenix disclaims any obligation to update any such forward-looking statement,forecast or estimates to reflect any change in the Company‟s expectations with regardthereto, or any change in events, conditions or circumstances on which any suchstatement, forecast or estimate is based. Notice  3 The next 30 minutes  TiGenix at a glance  The strategy and the execution    10 years of building the company    Why an IPO and listing on Euronext Brussels?    Corporate governance at TiGenix    4 FocusProductsPipelineLocationsFinanceRegenerative medicine - Innovative local treatmentsfor damaged and diseased joints ChondroCelect  ®  , autologous cell-based product forcartilage repair. First approved ATMP in Europe. Chondromimetic TM , resorbable implant for treatmentof osteochondral defects. Approved in Europe (CE)   Complementary regenerative medicine products,integrating biomaterials and adult stem cellsHQ in Leuven (Belgium); Manufacturing in Belgium,the Netherlands & Memphis (US); Cambridge (UK) Listed on Euronext Brussels since March ‟07  Raised in total mEUR 88 TiGenix at a glance
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks
SAVE OUR EARTH

We need your sign to support Project to invent "SMART AND CONTROLLABLE REFLECTIVE BALLOONS" to cover the Sun and Save Our Earth.

More details...

Sign Now!

We are very appreciated for your Prompt Action!

x